share_log

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target

RBC Capital重申对阿里拉姆制药的强劲表现,维持55美元的目标价。
Benzinga ·  11/02 00:33

RBC Capital analyst Gregory Renza reiterates Alnylam Pharmaceuticals (NASDAQ:AGIO) with a Outperform and maintains $55 price target.

RBC Capital分析师Gregory Renza重申纳斯达克:AGIO的阿里拉姆制药,评级为强劲表现,目标价格为55美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发